MPI 5020

Drug Profile

MPI 5020

Latest Information Update: 29 Aug 2002

Price : $50

At a glance

  • Originator Chiron Corporation
  • Class Radiosensitisers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Breast cancer; Cancer metastases

Most Recent Events

  • 19 Apr 1999 Clinical data have been added to the therapeutic trials section
  • 19 Apr 1999 Phase-II clinical trials for Cancer metastases in USA (Intratumoural)
  • 23 Jun 1998 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top